With operations in over 70 countries, Astellas Pharma specializes in the development and sale of pharmaceutical products, particularly in the areas of oncology, urology, and transplantation. The company's core products include anticancer agents, treatments for overactive bladder, and immunosuppressants for organ transplantation. Astellas has a strong focus on research and development, collaborating with academia, bio-ventures, and other pharmaceutical companies worldwide. The company's R&D strategy, known as the "Focus Area Approach," prioritizes sustainable and expandable drug discovery, with a particular emphasis on areas such as blindness and regeneration, mitochondria biology, genetic regulation, and immuno-oncology. Astellas also seeks to create healthcare solutions beyond medicine by leveraging its expertise and partnering with other organizations. Through strategic partnerships, licensing agreements, and mergers and acquisitions, Astellas aims to strengthen its commercialization platforms and address unmet medical needs.